Kate McKinley - 16 Dec 2023 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Role
Chief Business Officer
Signature
Kate McKinley
Issuer symbol
RANI
Transactions as of
16 Dec 2023
Net transactions value
$0
Form type
4
Filing time
19 Dec 2023, 16:05:09 UTC
Previous filing
08 Aug 2023
Next filing
22 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -250,000 -100% 0 16 Dec 2023 Class A Common Stock 250,000 $4.13 Direct F1, F2
transaction RANI Stock Option (Right to Buy) Award +250,000 250,000 16 Dec 2023 Class A Common Stock 250,000 $2.84 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest as follows: 25% of the shares subject to the option vest on May 22, 2024; and 1/48th of the shares subject to the option vest monthly over the remaining three years.
F2 The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.